Brain Research Bulletin
November 13, 2025
Xiang Liu, Ziyi Hua, Yongqiang Shu et al.
1 citation
This study aims to explore the relationship between the antidepressant effects of drugs (esketamine combined with sertraline) and brain function changes in patients with major depressive disorder. A total of 27 patients with major depressive disorder (MDD) and 27 healthy individuals were included in the study. All MDD patients received a 2-week course of intravenous esketamine infusion (0.25...
International Journal of Clinical Pharmacy
November 12, 2025
Qijing Liu, Ying Liu, Qian Fu et al.
2 citations
Current evidence suggests that ketamine/esketamine may be effective in alleviating POF, particularly in major abdominal surgeries. These findings should be interpreted cautiously due to the heterogeneity in study designs, variations in fatigue assessment tools and time, and the limited sample sizes of the included studies. Future high-quality RCTs are needed to confirm these observations and...
Neurotherapeutics
November 11, 2025
Zhaojuan Ke, Ying Zhang, Xin Jiang et al.
Ketamine exhibits superior efficacy compared to conventional antidepressants, yet its clinical application remains limited by dose-dependent side effects. Ascorbic acid (AA) augments ketamine's antidepressant-like effects, suggesting that AA co-administration with subtherapeutic ketamine doses may achieve optimal efficacy while improving safety. Since AA itself lacks independently clinical...
Research Square
November 11, 2025
Xuming Zhu, Xiaoyong Wei, Qianyu Guo et al.
preprint
Abstract Background: The incidence of preoperative anxiety in children is significantly higher than in adults. Esketamine, the dextrorotatory enantiomer of ketamine, has been shown to alleviate preoperative anxiety in children effectively. Previous studies have established the effective dose (ED 50 ) of esketamine for reducing anxiety in pediatric patients. However, the 95% effective dose (ED...
The Brown University Psychopharmacology Update
November 1, 2025
Twice‐weekly dosing of intranasal esketamine resulted in significant improvement in depressive symptoms compared with placebo in adults with treatment‐resistant depression, a 4‐week trial has found. Esketamine doses of 56 and 84 mg both outperformed placebo in the post‐marketing trial. Study results were published online July 2, 2025, in JAMA Psychiatry.
Translational Psychiatry
October 31, 2025
Giacomo D’andrea, Stefania Chiappini, Laura Ciavoni et al.
3 citations
BACKGROUND: Over the past ten years, several psychedelic compounds, including tryptamines like lysergic acid diethylamide/LSD, psilocybin, ayahuasca, and dimethyltryptamine/DMT, have been tested in clinical trials for a range of psychiatric conditions, such as anxiety and depression. While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are...
Journal of Psychiatric Research
October 30, 2025
Isabella S Ji, Morgan C H Cheng, Kayla M Teopiz et al.
2 citations
INTRODUCTION: Functional impairment is commonly reported amongst individuals with major depressive disorder (MDD) or treatment-resistant depression (TRD). Extant evidence suggests that ketamine and esketamine, N-methyl-D-aspartate (NMDA) receptor antagonists and glutamatergic modulators, have shown efficacy in treating MDD/TRD. While symptom reduction remains central to treatment, many...
Drug Design, Development and Therapy
October 29, 2025
Mengting Shen, Ye Xuan, Kaiyu Chen et al.
Background: Comorbid depressive symptoms are prevalent in patients with breast cancer, which adversely impacts postoperative recovery outcomes. Esketamine has emerged as a promising intervention for perioperative depression due to its rapid and sustained effects. This study aims to investigate the impact of the continuous intravenous infusion of esketamine during the perioperative period on...
Figshare
October 29, 2025
Background Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relative safety remains unclear. This review aims to update the evidence on the safety of two agents for MDD and indirectly compare their safety and tolerability. Method We systematically searched PubMed, PsycINFO, Embase, and Cochrane databases up to 1 May...
Brain Research Bulletin
October 27, 2025
Shu Wang, Wei Song, Yuanyuan Gao et al.
Background: Depression is a common complication of Parkinson disease (PD). This study investigated whether a single dose of esketamine could alleviate depressive symptoms in an MPTP mouse model by activating G protein-coupled receptor 109 A (GPR109A) and reducing neuroinflammation. Methods: Adult male C57BL/6 J mice (8 weeks, 25–30 g) were allocated into three groups: saline,...